In summary, our preclinical assessment for HOSU-53 provides strong rationale for clinical development in AML both as monotherapy and in combination with other targeted small molecule therapy and immune-based therapies, particularly with CD47 blockade, resulting in compelling curative potential in the AML disease model. The gene discussed is CD47; the disease is acute myeloid leukemia.